Eli Lilly Business Team Staffer to Head SYN X s Development Efforts | GenomeWeb

NEW YORK, March 12 – Aaron Davidson, previously a member of Eli Lilly’s corporate development team, has been named vice president of business development at SYN X Pharma, the company said Monday.

SYN X, a Toronto-based proteomics company is looking to launch deals for therapeutics and diagnostics stemming from the company’s initiatives.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.